DeepMed Research

DANA-FARBER CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1947-01-01

Employees: -

Market Cap: -

Website: http://www.dana-farber.org/

Clinical Trials

Hormone Suppression and Radiation Therapy for 6 Months With/Without Docetaxel for High Risk Prostate Cancer

Phase 3

Completed

Conditions: Prostate Cancer

Interventions: Drug: Androgen Hormonal Suppression and Radiation
Drug: Docetaxel
Drug: Androgen Suppression Therapy and Radiation Therapy

First Posted Date: 2005-06-28

Last Posted Date: 2022-01-11

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 350

Registration Number: NCT00116142

Locations: 🇺🇸
Dana-Farber Cancer Institute and (Sanofi-Aventis Consortium), Boston, Massachusetts, United States

Prostate Immobilization Device Used During Radiation Treatments to Decrease Rectal Bleeding

Phase 2

Completed

Conditions: Prostate Cancer

First Posted Date: 2005-06-21

Last Posted Date: 2023-05-03

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 100

Registration Number: NCT00114985

Title XELOX FOR SALIVARY GLAND CANCERS

Phase 2

Terminated

Conditions: Head and Neck Cancer

Interventions: Drug: Capecitabine
Drug: Oxaliplatin

First Posted Date: 2005-01-10

Last Posted Date: 2017-02-27

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 9

Registration Number: NCT00101075

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Thalidomide and Temozolomide in Relapsed or Progressive CNS Disease or Neuroblastoma

Phase 2

Completed

Conditions: Central Nervous System Tumor, Pediatric
Neuroblastoma

Interventions: Drug: temozolomide
Drug: thalidomide

First Posted Date: 2004-12-09

Last Posted Date: 2014-10-07

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 15

Registration Number: NCT00098865

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Talotrexin in Treating Patients With Advanced or Recurrent Solid Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: talotrexin ammonium

First Posted Date: 2004-12-08

Last Posted Date: 2017-12-18

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 53

Registration Number: NCT00098514

Locations: 🇺🇸
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, United States

Randomized Amifostine For SCCHN

Phase 2

Completed

Conditions: Head and Neck Cancer
Mucositis
Chemotherapeutic Agent Toxicity
Radiation Toxicity
Xerostomia

Interventions: Drug: Amifostine
Drug: Carboplatin
Radiation: radiation
Drug: Paclitaxel

First Posted Date: 2004-11-09

Last Posted Date: 2017-01-04

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 58

Registration Number: NCT00095927

Locations: 🇺🇸
Goodall Hospital, Sanford, Maine, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

and more 6 locations

Combination Chemotherapy and Radiation in Treating Patients With Stage III or IV Head and Neck Cancer (Paradigm Trial)

Phase 3

Completed

Conditions: Head and Neck Cancer

Interventions: Drug: carboplatin
Drug: cisplatin
Drug: docetaxel
Drug: fluorouracil

First Posted Date: 2004-11-09

Last Posted Date: 2013-11-19

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 145

Registration Number: NCT00095875

Locations: 🇺🇸
Rebecca and John Moores UCSD Cancer Center, La Jolla, California, United States
🇺🇸
Albert Einstein Cancer Center at Albert Einstein College of Medicine, Bronx, New York, United States
🇺🇸
Eugene M. and Christine E. Lynn Cancer Institute at Boca Raton Community Hospital - Main Campus, Boca Raton, Florida, United States

and more 12 locations

Capecitabine For Nasopharyngeal Cancer

Phase 2

Completed

Conditions: Head and Neck Cancer

Interventions: Drug: Capecitabine

First Posted Date: 2004-11-09

Last Posted Date: 2018-03-29

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 3

Registration Number: NCT00095901

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States

Letrozole in Preventing Breast Cancer in Postmenopausal Women

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Other: Placebo
Drug: Letrozole

First Posted Date: 2004-09-08

Last Posted Date: 2018-03-30

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 49

Registration Number: NCT00090857

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

and more 2 locations

Chemotherapy Plus Radiation Therapy in Treating Patients With Squamous Cell Cancer of the Head and Neck

Phase 1

Completed

Conditions: Head and Neck Cancer

Interventions: Drug: Taxotere
Radiation: Radiation therapy

First Posted Date: 2004-08-13

Last Posted Date: 2017-01-19

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 22

Registration Number: NCT00003200

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Harvard Community Health Plan, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

and more 1 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy